Any thought on comparisons of AMBS and recent acti
Post# of 30025
Phase 2 and preclinical pipeline
$20M Lincoln Park LOC issued earlier this year.
Recent(Aug 2014) 100:1 R/S from .08 to $8.00
Uplisted to Nasdaq at $8.00
Proxy to increase shares outstanding from 22.5M to 60M
Overall current decrease in share price since R/S and uplisting is down only 5.1% even with additional shares being requested.